

Ulcerative Colitis

How does a new medicine (efmarodocokin alfa) compare to available medicine and placebo – in people with ulcerative colitis

Trial Status
Completed

Trial Runs In
15 Countries

Trial Identifier
NCT03558152 2017-002350-36
GA39925

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This phase 2, randomized, double-blind, placebo-controlled, parallel-group clinical trial – was done to study “efmarodocokin alfa”, a new medicine for the treatment of patients with ulcerative colitis (UC). This study compared how well efmarodocokin alfa works in comparison to vedolizumab and placebo – when given to people with UC. One hundred and ninety-five people took part at 71 study centers in 16 countries.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)	Phase 2
Sponsor	Phase

NCT03558152 2017-002350-36 GA39925
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years & ≤ 80 Years

Healthy Volunteers
No